Royal Bank of Canada Reaffirms Outperform Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "outperform" rating reissued by investment analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They presently have a $13.00 target price on the biotechnology company's stock, up from their previous target price of $11.00. Royal Bank of Canada's price objective would indicate a potential upside of 30.26% from the company's previous close.

A number of other equities research analysts also recently weighed in on BCRX. Needham & Company LLC raised their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Wedbush started coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. JMP Securities restated a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Stock Up 0.6 %

NASDAQ BCRX traded up $0.06 during trading hours on Tuesday, hitting $9.98. The company had a trading volume of 7,606,302 shares, compared to its average volume of 2,989,382. The business has a fifty day simple moving average of $7.87 and a 200-day simple moving average of $7.89. The firm has a market cap of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals has a fifty-two week low of $5.34 and a fifty-two week high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The business's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.28 earnings per share. Equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at approximately $32,000. GF Fund Management CO. LTD. bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $33,000. GAMMA Investing LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,449 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $46,000. Finally, R Squared Ltd acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $48,000. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.